Healthcare / BiotechnologyNasdaqGM
$11.80
-0.08 (-0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-138.3M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$875M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.5%
↓Gross Margin
N/A
•Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-110.1%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $125.6M · net income $-91.9M · FCF $-138.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $125.6M | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M | $122.7M | $156.7M | $40.6M | $46.1M | $109.0M | — | — | — | — |
| Net Income | $-91.9M | $-91.9M | $-232.6M | $-133.1M | $-55.2M | $82.6M | $-69.3M | $26.9M | $-70.4M | $-38.5M | $45.1M | $-17.6M | $-16.4M | $-60.3M | $-8.6M |
| EBITDA | $-47.2M | $-47.2M | $-186.2M | $-102.0M | $-45.7M | $51.3M | $-71.0M | $18.1M | $-76.1M | $-41.1M | $45.5M | $-17.2M | $-15.6M | $-9.8M | $-5.7M |
| EPS | -1.24 | -1.24 | -3.58 | -2.08 | -0.93 | 1.37 | -1.21 | 0.46 | -1.31 | -0.82 | 1.07 | -0.45 | -0.52 | -3.85 | -118.86 |
| Operating Margin | -141.4% | -141.4% | -161.5% | -75.8% | -50.1% | 15.9% | -62.6% | 8.8% | -195.5% | -93.4% | 40.4% | — | — | — | — |
| Net Margin | -73.2% | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -83.4% | 41.4% | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.30 | 0.30 | 0.34 | 0.38 | 0.08 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 6.57 | 6.57 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-138.3M | $-138.3M | $-211.7M | $-99.2M | $-18.9M | $-30.2M | $-15.5M | $57.0M | $-87.0M | $-38.9M | $93.7M | $24.7M | — | — | — |
| Returns | |||||||||||||||
| ROE | -14.5% | -14.5% | -34.3% | -20.1% | -7.6% | 11.3% | -12.1% | 4.5% | -13.5% | -12.2% | 13.4% | -10.8% | -27.7% | -81.9% | 5.2% |
| Valuation | |||||||||||||||
| P/B | 1.38 | 1.38 | 2.32 | 1.88 | 2.21 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 13.7% | 13.7% | -36.7% | 6.1% | — | 124.2% | -21.7% | 285.9% | -12.0% | -57.7% | — | — | — | — | — |
| EPS Growth | 65.4% | 65.4% | -72.1% | -123.7% | — | 213.2% | -363.0% | 135.1% | -59.8% | -176.6% | 337.8% | 13.5% | 86.5% | 96.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.58 → -1.24
Residual
+47.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.